Generalitat de Catalunya

TECHNOLOGY CENTERS IN CATALONIA

TECNIO certification and main R&D players in Catalonia


Header Tecnio
ALPHA-KETOGLUTARATE
Spanish Patent pending.

A new method that allows precise quantification of plasma concentrations of alpha-ketoglutarate as new biomarker of NASH (nonalcoholic fatty liver disease). This technology is oriented to the biochemistry and clinical market. The technology can be interesting for companies that develop commercial kits.

TECHNOLOGY DESCRIPTION

An accurate quantification of circulating α-ketoglutarate segregates patients with different degrees of steatosis. A new method for the accurate quantification of plasma alpha-ketoglutarate as a novel biomarker of NAFLD has been developed.

The association of morbid obesity and non-alcoholic fatty liver disease (NAFLD) carries a severe impact on human health. Liver biopsy is the sole procedure to unequivocally assess NAFLD diagnosis and clinical progression. Circulating α-ketoglutarate is able to differentiate obese patients with steatosis from those without steatosis.

BUSINESS OPPORTUNITY

Nowadays there are different non-invasive methods for NASH detection. Some of them are based on the treatment of nuclear magnetic resonance images which allow to detect if a patient suffers from liver inflammation. Others are based on the use of biomarkers for disease. There is a diagnostic kit to detect the level of liver fibrosis and another kit for detecting non-invasive Nash. Neither of them uses the alpha-ketoglutarate as biomarker.

The measurement of this biomarker may potentiate the search for a therapeutic approach, may decrease the need for liver biopsy and may be useful in the assessment of disease progression.

License. The most appropriate transfer would be the license to a third party to exploit the technology in the market.

APPLICATION

The technology can be applied to:
- The use as a biomarker of non-alcoholic fatty liver disease of plasma alpha-ketoglutarate.
- Reducing the need for a liver biopsy, particularly in patients with metabolic risk factor.
- The use of serum α-ketoglutarate as a biomarker useful for identifying the severity and / or the occurrence of hepatic steatosis.
- The distinction between obese patients with steatosis those who do not suffer, assessing the progression of NASH.
- Design a kit to detect and quantify the plasma concentration of alpha-ketoglutarate.

The global pharmaceutical market will have a continuous growth approaching the 1.2 trillion dollar in 2017.

Biotechnology

Medical technology industries. Hospital and associated foundations.

STATE OF MATURITY
Research
Development
Exploitation

The technology is in a lab level state.

STATE OF INTELLECTUAL AND INDUSTRIAL PROPERTY

Spanish Patent pending. EURECAT (25%). URV (55%). IISPV (20%).

ADDITIONAL MATERIAL
URV-Centre de Transferència de Tecnologia i Innovació de la URV
Bernardino García Ramírez
977 558 704
Unitat de Recerca Biomèdica
ALPHA-KETOGLUTARATE
Spanish Patent pending.

A new method that allows precise quantification of plasma concentrations of alpha-ketoglutarate as new biomarker of NASH (nonalcoholic fatty liver disease). This technology is oriented to the biochemistry and clinical market. The technology can be interesting for companies that develop commercial kits.

TECHNOLOGY DESCRIPTION

An accurate quantification of circulating α-ketoglutarate segregates patients with different degrees of steatosis. A new method for the accurate quantification of plasma alpha-ketoglutarate as a novel biomarker of NAFLD has been developed.

The association of morbid obesity and non-alcoholic fatty liver disease (NAFLD) carries a severe impact on human health. Liver biopsy is the sole procedure to unequivocally assess NAFLD diagnosis and clinical progression. Circulating α-ketoglutarate is able to differentiate obese patients with steatosis from those without steatosis.

BUSINESS OPPORTUNITY

Nowadays there are different non-invasive methods for NASH detection. Some of them are based on the treatment of nuclear magnetic resonance images which allow to detect if a patient suffers from liver inflammation. Others are based on the use of biomarkers for disease. There is a diagnostic kit to detect the level of liver fibrosis and another kit for detecting non-invasive Nash. Neither of them uses the alpha-ketoglutarate as biomarker.

The measurement of this biomarker may potentiate the search for a therapeutic approach, may decrease the need for liver biopsy and may be useful in the assessment of disease progression.

License. The most appropriate transfer would be the license to a third party to exploit the technology in the market.

APPLICATION

The technology can be applied to:
- The use as a biomarker of non-alcoholic fatty liver disease of plasma alpha-ketoglutarate.
- Reducing the need for a liver biopsy, particularly in patients with metabolic risk factor.
- The use of serum α-ketoglutarate as a biomarker useful for identifying the severity and / or the occurrence of hepatic steatosis.
- The distinction between obese patients with steatosis those who do not suffer, assessing the progression of NASH.
- Design a kit to detect and quantify the plasma concentration of alpha-ketoglutarate.

The global pharmaceutical market will have a continuous growth approaching the 1.2 trillion dollar in 2017.

Biotechnology

Medical technology industries. Hospital and associated foundations.

STATE OF MATURITY
Research
Development
Exploitation

The technology is in a lab level state.

STATE OF INTELLECTUAL AND INDUSTRIAL PROPERTY

Spanish Patent pending. EURECAT (25%). URV (55%). IISPV (20%).

ADDITIONAL MATERIAL
URV-Centre de Transferència de Tecnologia i Innovació de la URV
Bernardino García Ramírez
977 558 704
Unitat de Recerca Biomèdica